


OncoPortal™ Plus is an evidence-based software curated by experts to aid the clear and confident interpretation of tumor molecular profiles

With the rise of precision medicine and biomarker-driven drug approvals, molecular laboratories must aggregate an ever-increasing amount of information from multiple sources to interpret their genomic findings. OncoPortal™ Plus is an evidence-based software curated by experts to support fast, consistent, and accurate interpretation of clinically relevant biomarkers.

SAVE TIME

OncoPortal™ Plus is fully integrated into the streamlined SOPHiA DDM™ workflow


Access mode



INCREASE PRECISION

Reliable features place genomic biomarkers into a clinical context

KEY FEATURES



SIMPLIFY INTERPRETATION

The user-friendly interface and intuitive navigation streamlines variant interpretation

The screenshot displays the OncoPortal Plus interface with several key features highlighted:

- User annotations:** Shows variant annotations for ALK fusion, EGFR wild-type, and TMB high, all with a 100% patient tumor type.
- Filters:** Includes a quick filter for 'Patient tumor type' and 'Other tumor type'.
- Easy access to variant information:** Shows a list of clinical associations for Alectinib, Brigatinib, and Ceritinib, with filters for 'Lung non-small cell carcinoma' and 'sensitive'.
- Clinical trial information:** Provides details for Brigatinib (AP26113), including its regulatory approval (FDA approved - Has Companion Diagnostic) and supporting literature (Phase III trial ALTA-1L).
- Drug cards:** A detailed card for Brigatinib (AP26113) showing its regulatory approval and supporting literature.

AMP/ASCO/CAP tier Cancer type, susceptibility, guidelines, regulatory approval, and clinical trials for therapy/therapies, with variant tiering Supporting literature One-click addition and removal from report

Customizable clinical trial search

The screenshot shows a search interface for clinical trials with the following details:

- Search criteria:** SID2023TSO001-SNV-FUS-R, Non-small cell lung cancer (NSCLC).
- Filters:** Recruiting, Phase III, adult senior, Patient disease(s), United States.
- Study description:** A Study Evaluating The Efficacy And Safety Of Multiple therapies In Cohorts Of Participants With Locally Advanced, unresectable, Satge III Non-Small Cell Lung Cancer (NSCLC).
- Recruitment status:** Recruiting.
- Analysis ID:** 47512, Date of analysis: 26/04/2024.
- Gene panel:** SOPHiA DDM for ...
- MSI:** N/A, **TMB (all):** N/A.
- MY REPORT:** 0 Profiles, 0 Clinical Associations.

The OncoPortal™ Plus Clinical Knowledgebase

- Powered by the Genomenon Clinical Knowledgebase (CKB)¹**
A professionally curated, up-to-date knowledgebase for interpreting complex cancer genomic profiles and connecting variants to available clinical trials and therapies
- Manually expanded with curations and user contributions**
For example, >450 genomic variants leading to MET exon 14 skipping
- Many types of biomarker**
SNVs/Indels, fusions, CNVs, TMB/MSI, wild-types
- Broad coverage**
More than 1,900 genes, 45,000 variants, 13,000 clinical trials, 4,000 targeted therapies

OncoPortal™ Plus is an oncology knowledgebase that compiles all relevant clinical insights in one place to:

- Reduce time per case** (Icon: Hourglass)
- Increase precision** (Icon: Target)
- Simplify interpretation** (Icon: Network diagram)

WANT TO KNOW MORE ? Contact us at info@sophiagenetics.com

1. <https://ckb.jax.org/about/index>